Bio-Rad Laboratories, Inc. (BIO-B)
| Previous close | 279.91 |
| Open | 281.55 |
| Bid | 269.50 x 1400 |
| Ask | 279.10 x 800 |
| Day's range | 279.91 - 281.55 |
| 52-week range | 271.00 - 467.95 |
| Volume | |
| Avg. volume | 275 |
| Market cap | 7.917B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -21.83 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksAnalysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireBio-Rad Announces Life Science Group Management Changes
HERCULES, Calif., April 26, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024. He succeeds Dr. Simon May, who has announced his decision to leave the company to pursue another professional opportunity.
ZacksNew Strong Sell Stocks for April 19th
ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.
